J&J suspends COVID-19 vaccine sales forecast

Johnson & Johnson is suspending sales forecasts for its COVID-19 vaccine only a few months after saying the shot could bring in as much as $3.5 billion this year. A global supply surplus and uncertainty about future demand — fueled in part by vaccine hesitancy in some developing markets — prompted the change, J&J said Tuesday.